Physician profile
Tejon Woods
NPI 1285911214
$8,375.86
in general payments reported to CMS, 2019-2025
26 companies · $4,977 in 2025
The $4,977 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2023: $50.10 · 2024: $3,041 · 2025: $4,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,956 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,956.34 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,449.92 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $1,303.28 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,058.82 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $968.17 | 2024-2025 | Invega Sustenna, Invega Trinza |
| Abbvie INC. | $646.86 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $539.11 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $504.39 | 2025 | Cobenfy |
| Alkermes, INC. | $386.92 | 2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $339.73 | 2024-2025 | Auvelity |
| Bausch Health US, LLC | $141.72 | 2024-2025 | Aplenzin |
| Lundbeck LLC | $130.80 | 2024-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Boston Scientific Corporation | $125.00 | 2021 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2024 | Quviviq |
| Janssen Biotech, INC. | $122.71 | 2025 | Invega Sustenna |
| Bayer Healthcare Pharmaceuticals INC. | $110.57 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $105.48 | 2024-2025 | Loreev Xr |
| Bard Access Systems, INC. | $57.19 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $50.10 | 2023 | |
| Corium, LLC | $49.20 | 2024-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $49.18 | 2025 | |
| Collegium Pharmaceutical, INC. | $24.78 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $24.28 | 2024 | |
| Owp Pharmaceuticals, INC. | $17.37 | 2024 | Subvenite |
| Luye Pharma (USA) LTD. | $16.30 | 2025 | Erzofri Extended-Release |
| Angiodynamics, INC. | $15.27 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.71 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejon Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.